Virtual FISV Symposium on
SARS-CoV-2 Biology and COVID-19

Virtual FISV Symposium on
SARS-CoV-2 Biology and COVID-19

Current research and perspectives

16 September 2020

16 September 2020

Preliminary Programme

8:30

Informal start. People check their camera, connection, etc

9:00-9:10

Welcome

 

SESSION 1
Phylogenesis and evolution of pathogenic beta-coronaviruses

Chair: Federico Manuel Giorgi (Bologna)

9:10-9:30

Edward C. Holmes (The University of Sydney, NSW, Australia)
Zoonoses and the Emergence of COVID-19

9:30-9:50

Graziano Pesole (University of Bari Aldo Moro, Italy)
Comparative and Evolutionary Genomics of SARS-Cov-2

9:50-10:00

Talk 3 (to be selected among the abstracts)

10:00-10:20

Break

 

SESSION 2
Virus life cycle and structural biology

Chair: Martino Bolognesi (Milan)

10:20-10:40

Martin Walsh (Diamond Light Source, Didcot, UK)

10:40-11:00

Ralf Bartenschlager (University of Heidelberg, Germany)

11:00-11:10

Talk 3 (to be selected among the abstracts)

11:10-11:30

Break

 

SESSION 3
Therapeutic strategies

Chair: Gianni Sava (Trieste)

11:30-11:50

Johan Neyts (Rega Institute for Medical Research, KU Leuven, Belgium)

11:50-12:10

Talk 2

12:10-12:20

Talk 3 (to be selected among the abstracts)

12:20-14:00

Break

 

SESSION 4
Markers of diagnosis and pathology

Chair: Raffaele de Francesco (Milan)

14:00-14:20

Andrea Crisanti (University of Padua, Italy)

14:20-14:40

Viviana Simon (Icahn School of Medicine at Mount Sinai, New York, NY, USA)

14:40-15:00

Melanie Ott (University of California San Francisco, CA, USA)

15:00-15:10

Talk 3 (to be selected among the abstracts)

15:10-15:30

Break

 

SESSION 5
Virus-host cell interactions

Chair: Valeria Poli (Turin)

15:30-15:50

Susan Weiss (University of Pennsylvania, Philadelphia, PA, USA)
Coronavirus antagonism of double-stranded RNA induced antiviral pathways

15:50-16:10

Dmitry Korkin (Worcester Polytechnic Institute, MA, USA)

16:10-16:20

Talk 3 (to be selected among the abstracts)

16:20-16:40

Break

 

SESSION 6
Adaptive immunity and vaccines

Chair: Gennaro Ciliberto (Rome)

16:40-17:00

Andrea Carfì (ModeRNA Inc., Cambridge, MA, USA)
Rapid development of mRNA-1273: a vaccine against SARS-CoV-2

17:00-17:20

Antonio Lanzavecchia (University of Italian Switzerland, Lugano, Switzerland)

17:20-17:30

Talk 3 (to be selected among the abstracts)

17:30

Congress ends